In recent developments, HSBC decided to
downgrade the rating of Haleon stocks while maintaining the target at GBP4.20. However, Haleon is showing profitable growth which is anticipated to occur primarily in the second half of 2025. It also witnessed a surge on Monday leading to analysts positing it as a valuable low price pharma stock for investment perks. In other news,
Pfizer, Haleon's primary shareholder, sold a massive stake worth $3 billion and £2.4B in Haleon, reducing their hold to 7.3%. On the optimistic side,
Haleon executives have acquired shares under the reward plan, and the stock hit an impressive new 1-year high. As of now, the economic landscape seems slightly skewed as the Q4 organic growth estimates surpassed expectations, but the
2025 guidance resulted in a dip in the share market. Barclays have amped up Haleon's price target citing 'Top Tier' earnings quality for FY24.
Jefferies have maintained a buy rating on the stock, with the target at GBP4.50. In the midst of these fluctuations,
BlackRock, the global investment management company, updated its stake in Haleon, while executive transactions continued to show strategic progress.
Haleon Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Fri, 07 Mar 2025 09:04:26 GMT -
Rating 0
- Innovation 1
- Information 5
- Rumor -2
